In recent years, gamma delta T cells have raised a lot of expectations to be applied in tumor and cancer treatment for their exceptional abilities to recognize and kill transformed cells independently of human leukocyte antigen restriction. And there has been increasing interest in translating their potential characteristics into innovative cellular cancer immunotherapies. Despite the high potential of gamma delta T cells, the efficacy of gamma delta T cell immunotherapy is currently limited, with a lower response rate. In order to advance gamma delta T cell immunotherapy, global biotech companies pull out all their efforts, trying to make some achievements, as Creative Biolabs did.
Recent studies showed that gamma delta T cell repertoires (TCRs) provide the basis for their applications in cancer treatment. Analyzing the TCR repertoires may help to gain a better understanding of the immune system’s features and of the aetiology and progression of diseases, in particular those with unknown antigenic triggers. However, the TCR receptor diverges widely, resulting in a severe challenge to the work of analysis. As a result, scientists have created a number of analysis methods to provide a practical and effective way for gamma delta TCR repertoire analysis, including sanger sequencing, polymerase chain reaction assays, and flow cytometry.
Additionally, researchers must also conduct an investigation of the gamma delta TCR-ligand reaction before they can identify whether the ligand has a high affinity for the gamma delta TCR and further assess the effectiveness of the developed gamma delta T cell therapy. With the boom of biological techniques, several methods such as surface plasmon resonance, isothermal titration calorimetry, and X-ray crystallography are widely utilized for the identification and analysis of TCR-ligand reactions.
More importantly, the need for TCR generation plays a role in boosting gamma delta T cell therapy. Whether it is αβ T cells or γδ T cells, the activation and various functions of T lymphocytes are both mediated by the surface TCR. Therefore, the significance of TCR generation does not require more explanation.
As an expert in gamma delta T cell therapy development, Creative Biolabs has assembled a group of elite scientists and established a unique development platform to ensure each project’s success. The company provides a comprehensive set of services regarding gamma delta T cell immunotherapy and tailored services based on customers’ needs, including but not limited to gamma delta T cell repertoire analysis, TCR-ligand reaction analysis, and generation services. Meanwhile, professional consultations are available for customers to address their scientific and technical issues throughout the project’s development.